URGN - Company ID 0001668243
The table below shows UroGen Pharma Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $50.96M | $27.48M | $24.21M | $20.25M | $24.57M | $25.20M |
| Cost of revenue | $4.14M | $3.28M | $3.55M | $2.33M | - | $2.45M |
| Gross profit | $46.82M | $24.20M | $20.66M | $17.92M | $22.09M | $22.75M |
| R&D | $15.60M | $14.01M | $18.91M | $19.87M | - | $11.36M |
UroGen Pharma Ltd. reported annual revenue of $109.79M for fiscal year 2025. That is up 21.4% from $90.40M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $17.53M (FY 2016) to $109.79M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $51.49M | $37.58M | $43.20M | $34.97M | - | $28.94M |
| Operating income | -$20.26M | -$27.39M | -$41.45M | -$36.91M | - | -$17.55M |
| Income tax | -$4.77M | -$1.05M | $1.01M | $392.00K | - | $91.00K |
| Net income | -$23.57M | -$33.35M | -$49.94M | -$43.84M | -$37.51M | -$23.67M |
| EPS (diluted) | - | - | - | - | - | - |